Long acting GLP-1 analogues were later approved for obesity based upon early observations that physiologic and pharmacologic GLP-1R agonism reduces food intake in preclinical models (12) and pioneering clinical trials of long acting GLP-1 analogues (13). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.